MAXCYTE INC
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
MXCT$1.30+3.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · March 31, · · December 31, | ||||||
| · 2024 · 2023 | ||||||
| | | | (Unaudited) | | | (See Note 2) |
| Assets · · · · · | ||||||
| Current assets: · · | ||||||
| Cash and cash equivalents | | $22,249 | | $46,506 | ||
| Short-term investments, at amortized cost | | 135,264 | | 121,782 | ||
| Accounts receivable, net | | 5,991 | | 5,778 | ||
| Inventory | | 11,960 | | 12,229 | ||
| Prepaid expenses and other current assets | | 3,210 | | 3,899 | ||
| Total current assets | | 178,674 | | 190,194 | ||
| | | | | | | |
| Investments, non-current, at amortized cost | | | 45,031 | | | 42,938 |
| Property and equipment, net | | | 22,805 | | 23,513 | |
| Right-of-use asset - operating leases | | | 11,125 | | 11,241 | |
| Other assets | | 295 | | 388 | ||
| Total assets | | $257,930 | | $268,274 | ||
| | | | | | | |
| Liabilities and stockholders’ equity | | | ||||
| Current liabilities: | | | ||||
| Accounts payable | | $1,674 | | $743 | ||
| Accrued expenses and other | | 6,502 | | 11,269 | ||
| Operating lease liability, current | | 825 | | 774 | ||
| Deferred revenue, current portion | | 4,476 | | 5,069 | ||
| Total current liabilities | | 13,477 | | 17,855 | ||
| | | | | | | |
| Operating lease liability, net of current portion | | 17,815 | | 17,969 | ||
| Other liabilities | | 279 | | 283 | ||
| Total liabilities | | 31,571 | | 36,107 | ||
| | | | | | | |
| Commitments and contingencies (Note 7) | | | ||||
| Stockholders’ equity | | | ||||
| Preferred stock, $0.01 par value; 5,000,000 shares authorized and no shares issued and outstanding at March 31, 2024 and December 31, 2023 | | | — | | | — |
| Common stock, $0.01 par value; 400,000,000 shares authorized, 104,405,111 and 103,961,670 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | | | 1,044 | | | 1,040 |
| Additional paid-in capital | | 410,639 | | 406,925 | ||
| Accumulated deficit | | (185,324) | | (175,798) | ||
| Total stockholders’ equity | | 226,359 | | 232,167 | ||
| Total liabilities and stockholders’ equity | | $257,930 | | $268,274 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.